GRAIL Future Growth
Future criteria checks 1/6
GRAIL is forecast to grow earnings and revenue by 35.7% and 17.9% per annum respectively while EPS is expected to grow by 50.8% per annum.
Key information
35.7%
Earnings growth rate
50.8%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 17.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 15 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 169 | -588 | -402 | -394 | 1 |
| 12/31/2025 | 138 | -663 | -464 | -456 | 2 |
| 12/31/2024 | 120 | -2,107 | -649 | -641 | 2 |
| 9/30/2024 | 118 | -2,117 | -621 | -613 | N/A |
| 6/30/2024 | 110 | -2,883 | -676 | -665 | N/A |
| 3/31/2024 | 100 | -1,491 | -645 | -633 | N/A |
| 12/31/2023 | 93 | -1,466 | -609 | -596 | N/A |
| 1/1/2023 | 56 | -5,399 | -584 | -561 | N/A |
| 1/2/2022 | 15 | -1,248 | -758 | -688 | N/A |
| 6/30/2021 | 1 | -387 | -363 | -295 | N/A |
| 3/31/2021 | 0 | -350 | -303 | -263 | N/A |
| 12/31/2020 | N/A | -312 | -244 | -232 | N/A |
| 9/30/2020 | N/A | -284 | -215 | -212 | N/A |
| 6/30/2020 | N/A | -264 | -215 | -213 | N/A |
| 3/31/2020 | N/A | -254 | -232 | -229 | N/A |
| 12/31/2019 | N/A | -245 | -249 | -246 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NL0 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NL0 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NL0 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NL0's revenue (17.9% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: NL0's revenue (17.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NL0's Return on Equity is forecast to be high in 3 years time